Evidence item

The estimates are adjusted observational test-negative results pooled across 32 hospitals in seven Indian states, with wide confidence intervals and 638 ELISA-positive cases among 2,243 children. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25981

Source: Effectiveness of the oral rotavirus vaccine ROTASIIL among children hospitalized with acute gastroenteritis in India · locator {} · excerpt hash sha256:305a22eaae608d13b07fca6f3bd792c51f6e08ec7320c37c7b79990e11299bd0

Exact excerpt

Primary endpoint was vaccine effectiveness (VE) against moderate and severe rotavirus gastroenteritis (RVGE) in children <2 years using pooled data from two multi-center observational studies across 32 hospitals in seven states (July 2019–December 2023). A test-negative case–control design estimated adjusted VE (aVE) for three ROTASIIL® doses. Among 2,243 children aged 3–23 months hospitalized with acute gastroenteritis, 638 were ELISA-positive. For completed series (three doses), the aVE against moderate RVGE was 56% (CI, 11-79), and that of severe RVGE was 54% (CI, 31-70).

Linked claims

Claim	Direction	Relevance	Steps	Counted
41658c9a	QUALIFY	DIRECT	0	yes

Audits

None.